Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and PATRICK HWU.
ALEXANDER LAZAR
Connection Strength
1.925
PATRICK HWU
  1. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
    View in: PubMed
    Score: 0.215
  2. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol. 2008 Dec; 5(12):737-40.
    View in: PubMed
    Score: 0.083
  3. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
    View in: PubMed
    Score: 0.055
  4. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.
    View in: PubMed
    Score: 0.055
  5. Multi-modal molecular programs regulate melanoma cell state. Nat Commun. 2022 07 09; 13(1):4000.
    View in: PubMed
    Score: 0.054
  6. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.053
  7. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
    View in: PubMed
    Score: 0.053
  8. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.052
  9. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.051
  10. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.050
  11. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.050
  12. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.048
  13. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
    View in: PubMed
    Score: 0.046
  14. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.
    View in: PubMed
    Score: 0.045
  15. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.045
  16. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
    View in: PubMed
    Score: 0.045
  17. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
    View in: PubMed
    Score: 0.043
  18. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.042
  19. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.042
  20. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.042
  21. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.041
  22. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
    View in: PubMed
    Score: 0.040
  23. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud. 2018 04; 4(2).
    View in: PubMed
    Score: 0.040
  24. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.039
  25. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.039
  26. High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. Transl Oncol. 2017 Aug; 10(4):546-554.
    View in: PubMed
    Score: 0.038
  27. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017; 7:11.
    View in: PubMed
    Score: 0.038
  28. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology. 2017; 6(6):e1321187.
    View in: PubMed
    Score: 0.037
  29. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.
    View in: PubMed
    Score: 0.037
  30. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.037
  31. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.036
  32. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.036
  33. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.036
  34. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.035
  35. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.034
  36. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.031
  37. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
  38. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.
    View in: PubMed
    Score: 0.029
  39. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012 Sep; 39(9):821-5.
    View in: PubMed
    Score: 0.027
  40. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
    View in: PubMed
    Score: 0.026
  41. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15; 118(16):4014-23.
    View in: PubMed
    Score: 0.026
  42. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009 Aug; 8(8):2079-85.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.